Industry Connectwith Brandon Capital Partners Pty Ltd
CUREator – biomedical ‘valley of death’ funding, backed by the MRFF, delivered by MRCF.
Expressions of Interest now open!
The Medical Research Future Fund (MRFF) has recently been awarded $40 million funding to Brandon Capital Partners’ Medical Research Commercialisation Fund (MRCF). MRCF has established CUREator to provide funding to support two streams of early stage Australian medical research translation and commercialisation.
Stream 1: preclinical biomedical projects with commercial potential. CUREator’s aim is to fund at least 25 projects over 3 years providing $500k-$1m per project to develop the product opportunity to a point that it is ready for venture capital investment.
Stream 2: early clinical development of novel drugs, or novel uses for existing drugs, with commercial potential. CUREator’s aim is to fund at least 11 projects with up to $1.5m per project over 3 years. Stream 2 projects will be matched 1:1 with venture capital from the MRCF.
Researchers are cordially invited to attend an information session with Dr Goslik Schepers, Senior Investment Manager, Brandon Capital Partners Pty Ltd when he will provide additional information on CUREator and the application process.
Expressions of Interests (EOIs) for Round 1 opened on 11 November and close on 6 December 2021 at 3:00pm AEST.
Don’t miss this information session to find out more!
Event details
Time
12:00pm - 1:00pm
Date
Wednesday, 17 November 2021
Venue
Room 275, Level 2
GCI (#20), St Lucia Campus
VIA ZOOM
RSVP
rsvp@uniquest.com.au
for Zoom details or to register for in person attendance
For more information in your research area, contact:
Dr Craig Belcher
Senior Director & Head of Life Sciences
c.belcher@uniquest.com.au
